3.2.1 allergy and/or hypersensitivity to csa. 3.2.2 gfr\<30 ml/min. 3.2.3 alt (alanine transaminase) or ast (aspartate transaminase) \>3x upper limits of normal. 3.2.4 resistant hypertension (bp\>140/90 mm hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 active bacterial or mycobacterial infection. 3.2.6 pregnant and/or nursing patients. 3.2.7 participation in a covid-19 therapeutic drug trial. 3.2.8 patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 total cholesterol is \< 100 (increased risk of seizure) 3.2.11 concomitant dosing with tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 concomitant malignancy is a relative contraindication (neoral can increase susceptibility to development of neoplasia) 3.2.13 inability to swallow oral medication 3.2.14 treatment with immunomodulators or immunosuppressant drugs, including but not limited to il-6 inhibitors, tnf inhibitors, anti-il-1 agents, and jak inhibitors. 3.2.15 investigational antiviral agents

3.2.1 allergy and/or hypersensitivity to csa. 3.2.2 gfr\<30 ml/min. 3.2.3 alt (alanine transaminase) or ast (aspartate transaminase) \>3x upper limits of normal. 3.2.4 resistant hypertension (bp\>140/90 mm hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 active bacterial or mycobacterial infection. 3.2.6 pregnant and/or nursing patients. 3.2.7 participation in a covid-19 therapeutic drug trial. 3.2.8 patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 total cholesterol is \< 100 (increased risk of seizure) 3.2.11 concomitant dosing with tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 concomitant malignancy is a relative contraindication (neoral can increase susceptibility to development of neoplasia) 3.2.13 inability to swallow oral medication 3.2.14 treatment with immunomodulators or immunosuppressant drugs, including but not limited to il-6 inhibitors, tnf inhibitors, anti-il-1 agents, and jak inhibitors. 3.2.15 investigational antiviral agents

3.2.1 allergy and/or hypersensitivity to csa. 3.2.2 gfr<30 ml/min. 3.2.3 alt (alanine transaminase) or ast (aspartate transaminase) >3x upper limits of normal. 3.2.4 resistant hypertension (bp>140/90 mm hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 active bacterial or mycobacterial infection. 3.2.6 pregnant and/or nursing patients. 3.2.7 participation in a covid-19 therapeutic drug trial. 3.2.8 patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 total cholesterol is < 100 (increased risk of seizure) 3.2.11 concomitant dosing with tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 concomitant malignancy is a relative contraindication (neoral can increase susceptibility to development of neoplasia) 3.2.13 inability to swallow oral medication 3.2.14 treatment with immunomodulators or immunosuppressant drugs, including but not limited to il-6 inhibitors, tnf inhibitors, anti-il-1 agents, and jak inhibitors. 3.2.15 investigational antiviral agents

3.2.1 allergy and/or hypersensitivity to csa. 3.2.2 gfr<30 ml/min. 3.2.3 alt (alanine transaminase) or ast (aspartate transaminase) >3x upper limits of normal. 3.2.4 resistant hypertension (bp>140/90 mm hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 active bacterial or mycobacterial infection. 3.2.6 pregnant and/or nursing patients. 3.2.7 participation in a covid-19 therapeutic drug trial. 3.2.8 patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 total cholesterol is < 100 (increased risk of seizure) 3.2.11 concomitant dosing with tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 concomitant malignancy is a relative contraindication (neoral can increase susceptibility to development of neoplasia) 3.2.13 inability to swallow oral medication 3.2.14 treatment with immunomodulators or immunosuppressant drugs, including but not limited to il-6 inhibitors, tnf inhibitors, anti-il-1 agents, and jak inhibitors. 3.2.15 investigational antiviral agents

3.2.1 allergy and/or hypersensitivity to csa. 3.2.2 gfr<30 ml/min. 3.2.3 alt or ast >3x upper limits of normal. 3.2.4 resistant hypertension (bp>140/90 mm hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 active bacterial or mycobacterial infection. 3.2.6 pregnant and/or nursing patients. 3.2.7 participation in a covid-19 therapeutic drug trial. 3.2.8 patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 total cholesterol is < 100 (increased risk of seizeure) 3.2.11 concomitant dosing with tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 concomitant malignancy is a relative contraindication (neoral can increase susceptibility to development of neoplasia)

3.2.1 allergy and/or hypersensitivity to csa. 3.2.2 gfr<30 ml/min. 3.2.3 alt or ast >3x upper limits of normal. 3.2.4 resistant hypertension (bp>140/90 mm hg despite adherence to maximal doses of three antihypertensive agents). 3.2.5 active bacterial or mycobacterial infection. 3.2.6 pregnant and/or nursing patients. 3.2.7 participation in a covid-19 therapeutic drug trial. 3.2.8 patients who have received or who are receiving anti-viral medications including hydroxychloroquine will not be excluded. 3.2.9 patients with psychiatric illness/social situations that would limit compliance with study requirements. 3.2.10 total cholesterol is < 100 (increased risk of seizeure) 3.2.11 concomitant dosing with tacrolimus is a relative contraindication (increases overall immunosuppression and decrease seizure threshold 3.2.12 concomitant malignancy is a relative contraindication (neoral can increase susceptibility to development of neoplasia)